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ABSTRACT
Objectives: The study aimed to assess the associations between circulating vaspin levels and nutritional status (assessed 
on tha basis of BMI) as well as insulin resistance in PCOS.
Material and methods: Eighty-seven PCOS women, 48 obese and 39 normal weight, were enrolled in the cross-sectional 
study. Seventy-two Non-PCOS women, 41 obese and 31 normal weight, constituted a control group. Body mass, height and 
waist circumference as well as body composition by bioimpedance were measured. In the morning (16h after the last meal) 
we determined: serum glucose, insulin, androgens, gonadotropin (LH, FSH) and sex hormone-binding globulin (SHBG) as 
well as plasma vaspin levels. Standard HOMA-IR formula was used to assess insulin resistance (IR). 
Results: Plasma vaspin levels were significantly lower in PCOS, both normal weight and obese, than in Non-PCOS 
groups. Vaspin levels were similar in normal weight and obese PCOS subgroups. There was no association between plasma 
vaspin levels and anthropometric parameters in PCOS group. While in Non-PCOS group a negative correlation between 
plasma vaspin levels and body mass (r = –0.26; p < 0.05) was found. We did not observe correlations between plasma vaspin 
levels and serum glucose and insulin concentrations as well as HOMA-IR values, however, in multivariable, stepwise backward 
regression waist circumference and HOMA-IR values explained 18.0% of plasma vaspin levels variability in the study subjects. 
Conclusions: PCOS occurrence is associated with decreased vaspin levels. The influence of nutritional status on vaspin level 
observed in Non-PCOS is abolished in PCOS women, possibly by more severe insulin resistance. 
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INTRODUCTION
Vaspin is an adipokine, the member of the serine pro-
tease inhibitors family (serpin) [1]. Vaspin mRNA expression 
was found in subcutaneous and visceral adipose tissue, liver, 
pancreas, stomach and skin [2–5]. 
The experimental studies have shown that vaspin in-
creased insulin sensitivity and glucose tolerance as well as 
decreased food intake [4, 6]. Expression of vaspin mRNA 
in rats visceral adipose tissue increased with an excess of 
body mass and insulin resistance [1]. In addition, factors 
252
Ginekologia Polska 2020, vol. 91, no. 5
www. journals.viamedica.pl/ginekologia_polska
stimulating vaspin expression were leptin and metformin 
and inhibiting night break in food intake [7]. 
In the human expression of vaspin mRNA in visceral 
adipose tissue was proportional to BMI value and body fat 
percentage. In turn, this expression in subcutaneous adipose 
tissue was proportional to WHR values and fasting serum 
insulin levels [2]. The association between plasma vaspin 
levels and BMI values and insulin resistance was also shown 
in another study [8]. Plasma vaspin levels were higher in 
women than in men [8]. It is suggested that this sex differ-
ence develops during puberty [3]. However, in subjects with 
metabolic and cardiovascular disturbances the association 
between circulating vaspin levels and BMI values, sex and 
age were not observed [9, 10]. 
It has been suggested that increase vaspin mRNA expres-
sion and its secretion are a compensatory mechanism that 
delays insulin resistance development [2, 8, 11]. However, the 
results of other studies did not confirm this hypothesis [10–13]. 
Several projects assessing vaspin levels in PCOS showed 
inconclusive results. Higher vaspin levels were observed in 
normal-weight PCOS than in Non-PCOS women [14–16]. On 
the other hand, there were no differences between over-
weight/obese PCOS and Non-PCOS women [16]. In addition, 
serum testosterone levels, FAI values and mean ovary vol-
ume or the number of follicles were proportional to vaspin 
levels. While serum FSH and SHBG levels, as well as insulin 
sensitivity, were inversely related to vaspin levels [16]. The 
highest plasma vaspin levels were shown in the phenotype 
A, thus this parameter is considered as the marker of the 
severity of PCOS [17]. The lack of differences between plasma 
vaspin levels in adolescents with or without PCOS has also 
been shown [18]. Similarly, vaspin levels did not differ be-
tween normal-weight PCOS and Non-PCOS women in Ira-
nian population, despite higher insulin levels in PCOS group 
[19]. In turn, treatment with metformin and improvement of 
the insulin sensitivity caused a decrease in vaspin levels [14]. 
However, Koiou et al. [16] have shown only a slight effect of 
treatment with metformin on vaspin levels in normal-weight 
PCOS women and lack of the impact of moderate weight 
loss on vaspin levels in overweight and obese PCOS women. 
The study aimed to assess the associations between 
circulating vaspin levels and nutritional status (assessed 
on the basis of BMI) as well as insulin resistance in PCOS.
MATERIAL AND METHODS 
Eighty-seven PCOS (diagnosed on the basis of Rot-
terdam ESHRE/ASRM criteria [20]) women, 48 obese and 
39 normal-weight, were enrolled in the cross-sectional 
study. Seventy-two Non-PCOS women, 41 obese and 31 nor-
mal weight, constituted the control group. The exclusion 
criteria included any pharmacotherapy, alcohol and nicotine 
addiction and changes of body mass over 2 kg during the 
last 3-months. The written informed consent was obtained 
from all subjects. The Bioethical Committee of the Medical 
University of Silesia approved the study protocol. 
Nutritional status was diagnosed on the basis of BMI values 
in accordance with World Health Organization criteria. Table 
1 presents the characteristics of the study and control groups.
The venous blood samples (15 mL) for laboratory tests 
were collected in the morning 16 hours after the last meal 
Table 1. Patients characteristics’
PCOS non-PCOS
All  
(n = 87)
Normal weight  
(n = 39)
Obese  
(n = 48)
All  
(n = 72)
Normal weight 
(n = 31)
Obese  
(n = 41)
Age [years] 25.4 ± 5.5 23.7 ± 4.5++ 26.8 ± 5.8 26.4 ± 5.5 23.8 ± 4.3$$$ 28.4 ± 5.6
Body mass [kg] 79.4 ± 26.4 56.9 ± 11.7***+++ 97.7 ± 20.2&&& 78.7 ± 20.4 59.8 ± 7.1$$$ 93.1 ± 14.6
BMI [kg/m2] 28.6 (20.8–35.7) 20.6***+++ (19.6–22.7) 35.1&&& (31.3–40.2) 28.5 (22.9–33.5) 22.4$$$ (21.0–24.0) 32.9 (30.3–36.7)
Body fat [kg] 30.2 (15.4–42.6) 15.0**++ (12.6–19.7) 40.6&& (33.4–56.3) 33.3 (19.1–50.4) 18.1$$ (14.8–20.6) 49.4 (37.5–50.2)
Body fat [%] 38.1 (27.5–45.7) 26.5***+++ (24.2–31.0) 44.8&&& (41.9–51.1) 40.6 (30.4–48.5) 30.0$$$ (26.8–33.9) 46.8 (42.3–51.4)
Waist circumference [cm] 89.8 ± 18.7 72.6 ± 7.3***+++ 103.7 ± 12.3&&& 87.9 ± 18.2 70.5 ± 8.3$$$ 101.0 ± 11.3
Total cholesterol [mg/dL] 176.3 ± 34.0 167.7 ± 28.1* 183.2 ± 37.0 174.6 ± 30.6 169.1 ± 33.3 178.8 ± 27.5
LDL- cholesterol[mg/dL] 105.4 ± 38.3 93.8 ± 27.5** 115.1 ± 37.6 100.3 ± 27.1 90.3 ± 31.9 106.4 ± 21.9
HDL- cholesterol [mg/dL] 45.7 ± 14.1%%% 48.1 ± 15.1*## 43.8 ± 12.9&&&^^^ 57.1 ± 15.2 60.1 ± 16.3$ 54.8 ± 14.2
Triglycerides [mg/dL] 100.7 ± 55.2 73.0 ± 31.7**## 121.5 ± 61.4&&^^ 80.1 ± 32.1 67.2 ± 26.7$$ 89.9 ± 32.6
Glucose [mmol/L] 5.1 ± 0.8%%% 4.9 ± 0.7## 5.3 ± 0.9&&^^ 4.7 ± 0.4 4.7 ± 0.5 4.7 ± 0.4
Insulin [μIU/mL] 10.6%% (7.8–15.1) 8.4** (6.0–10.6) 12.9&&^^ (9.7–18.6) 7.4 (5.9–9.5) 6.8 (5.6–8.7) 7.8 (6.3–10.0)
HOMA-IR 2.3%% (1.6–3.2) 1.8** (1.2–2.3) 2.8&&^^ (1.2–4.1) 1.5 (1.2–2.0) 1.5 (1.1–1.9) 1.7 (1.4–2.2)
*p < 0.05; **p < 0.01; ***p < 0.001 normal weight PCOS vs obese PCOS; #p < 0.05; ##p < 0.01; ###p < 0.001 normal weight PCOS vs normal weight non-PCOS; +p < 0.05; ++p < 0.01; 
+++p < 0.001 normal weight PCOS vs obese non-PCOS; & p < 0.05; &&p < 0.01; &&&p < 0.001 obese PCOS vs normal weight non-PCOS; ^p < 0.05; ^^p < 0.01; ^^^p < 0.001 obese 
PCOS vs obese non-PCOS; $p < 0.05; $$p < 0.01; $$$p < 0.001 normal weight non- PCOS vs obese non-PCOS; %p < 0.05; %%p < 0.01; %%%p < 0.001 all PCOS vs all non-PCOS
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between 3–5 days of the menstrual cycle. Height, body mass 
and waist circumference were measured. BMI was calculat-
ed. The bioimpedance method (Bodystat 1500, Douglas, Isle 
of Man) was used to the assessment of body composition. 
Serum and plasma samples were stored frozen in –70°C.
Laboratory procedures 
Calorimetric methods (kits made by Roche, Switzerland) 
were used to determine serum glucose and lipids. Fast-
ing serum insulin levels were measured by enzyme-linked 
immunosorbent assay — ELISA (DRG Instruments GmbH, 
Marburg, Germany) with a lower limit of detection of 
1.76 mIU/mL. The insulin resistance was assessed on 
the basis of HOMA-IR = fasting concentration of insulin 
(mIU/mL) × fasting concentration of glucose (mmol/L)/22.5.
The ELISA (DRG Instruments GmbH, Marburg, Germany) 
method was also used to determine concentrations of gon-
adotropin (FSH, LH), prolactin (PRL), estradiol (E2), androgens 
(testosterone, free testosterone, androstenedione, DHEA-S) 
as well as plasma vaspin levels (BioVendor, Brno, The Czech 
Republic) with the lower limit of detection of 0.01 ng/mL 
and intra-assay coefficient variation 7.6% and inter-assay 
coefficients variation 7.65%.
In addition, with the standard formula, the free andro-
gen index (FAI) was calculated.
Statistic analysis
STATISTICA 9.0 PL (StatSoft Poland) software and R soft-
ware environment were used for statistical analysis. There 
was no missing data in the database. The mean values ± stan-
dard deviation and median with upper and lower quar-
tiles were used for the presentation of the results. The 
D’Agostino-Pearson test was used to assess the distribu-
tion of variables. The Levene test was used to assess the 
homogeneity of variances. Two-way multivariable analysis 
of variances with Duncan post-hoc test was used for com-
parison of quantitative variables. The multivariable linear 
regression with the backward stepwise procedure was used 
to assess the associations between variables. Cook’s distance 
values were used for identification of outliers. Testing the 
residuals for heteroskedasticity was performed using the 
Cook-Weisberg test. Models calculation was performed in-
cluding evaluation of multicollinearity, which was assessed 
with the variance inflation factor (VIF below 5). Additionally, 
how well it fit in the obtained model was also assessed with 
the F test and determination coefficient R2. Values below 
0.05 were considered statistically significant.
RESULTS
Body mass and BMI values were similar in the corre-
sponding PCOS and Non-PCOS subgroups. Significantly 
higher glucose and insulin levels as well as HOMA-IR and 
FAI values and lower HDL cholesterol and SHBG levels were 
found in PCOS in comparison to Non-PCOS group and obese 
than normal-weight PCOS subgroups (Tab. 1 and 2). 
Plasma vaspin levels were significantly lower in PCOS 
than in Non-PCOS group. The lower plasma vaspin lev-
els were shown in both PCOS and in the corresponding 
Non-PCOS subgroups. Similar plasma vaspin levels were 
found in normal weight and obese PCOS subgroups, while 
Table 2. Serum concentrations of hormones and plasma vaspin levels in analyzed groups of PCOS and non-PCOS
PCOS non-PCOS
All 
(n = 83)
Normal weight  
(n = 39)
Obese  
(n = 48)
All  
(n = 72)
Normal weight 
(n = 31)
Obese  
(n = 41)
FSH [mIU/mL] 5.7 (4.4–7.4) 5.5 (4.5–6.6) 5.9 (4.4–8.5) 5.4 (3.9–6.8) 5.4 (3.5–6.5) 5.5 (4.3–7.1)
LH [mIU/mL] 10.0%% (6.6–14.4) 8.2 (5.2–12.8) 10.9&& (8.2–15.6) 8.0 (6.0–12.2) 7.7 (6.4–9.2) 9.1 (4.0–15.4)
LH/FSH 1.7% (1.1–2.5) 1.6* (1.0–2.4) 1.7^ (1.2–2.6) 1.5 (0.9–2.5) 1.5 (1.1–2.5) 1.5 (0.6–2.5)
PRL [ng/mL] 5.9%%% (4.1–8.3) 4.6##++ (3.5–7.7) 6.8 (4.9–8.5) 8.1 (5.2–10.7) 7.8 (6.2–12.0) 8.4 (4.7–10.2)
Androstendione [ng/mL] 2.2 (1.5–3.3) 2.8**##++ (2.1–3.6) 1.9 (1.3–2.8) 1.9 (1.4–2.8) 2.1 (1.4–3.1) 1.8 (1.4–2.6)
DHEA-S [μg/mL] 2.7 (2.1–3.5) 2.7 (2.2–3.5) 2.8 (2.1–3.4) 2.6 (1.8–3.5) 2.7 (2.1–3.9) 2.4 (1.7–3.3)
Total testosterone [ng/mL] 0.7 (0.5–0.9) 0.7 (0.5–0.9) 0.6 (0.5–0.8) 0.6 (0.4–0.8) 0.6 (0.4–0.8) 0.6 (0.4–0.8)
Free testosterone [pg/mL] 1.8% (1.1–2.8) 2.1*#+ (1.4–3.1) 1.6 (1.1–2.6) 1.4 (0.8–2.3) 1.4 (0.9–2.3) 1.4 (0.8–2.3)
Estradiol [pg/mL] 41.9 (29.6–66.7) 43.6 (32.7–72.6) 40.0 (27.1–64.1) 56.5 (29.7–90.7) 56.8 (34.4–82.7) 54.9 (24.6–111.4)
SHBG [nmol/l] 23.0%% (14.8–37.3) 34.2**++ (17.3–49.9) 19.0&& (10.8–26.7) 30.7 (20.4–49.0) 38.6$$ (28.2–63.6) 22.9 (16.5–47.3)
FAI 3.1%% (1.7–4.9) 2.3**#+ (1.2–4.4) 3.3& (2.0–5.1) 1.7 (1.1–3.1) 1.5$ (0.9–2.2) 2.0 (1.3–4.4)
Vaspin [ng/mL] 0.13 (0.03–0.87) 0.13
###+++  
(0.04–0.87)
0.13&&&^^^  
(0.03–0.53) 0.18 (0.03–2.07) 0.16
$ (0.03–1.38) 0.19 (0.06–2.07)
*p < 0.05; **p < 0.01; ***p < 0.001 normal weight PCOS vs obese PCOS; #p < 0.05; ##p < 0.01; ###p < 0.001 normal weight PCOS vs normal weight non-PCOS; +p < 0.05; ++p < 0.01; 
+++p < 0.001 normal weight PCOS vs obese non-PCOS; &p < 0.05; &&p < 0.01; &&&p < 0.001 obese PCOS vs normal weight non-PCOS; ^p < 0.05; ^^p < 0.01; ^^^p < 0.001 obese 
PCOS vs obese non-PCOS; $p < 0.05; $$p < 0.01; $$$p < 0.001 normal weight non- PCOS vs obese non-PCOS; %p < 0.05; %%p < 0.01; %%%p < 0.001 all PCOS vs all non-PCOS
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lower plasma vaspin levels were observed in normal-weight 
than in obese Non-PCOS subgroups (Tab. 2).
Correlation between plasma vaspin levels 
and anthropometric parameters and insulin 
resistance 
We did not observe any association between plasma 
vaspin levels or any anthropometric parameters in all study 
groups and the PCOS group. While in Non-PCOS group the 
negative correlation between plasma vaspin levels and body 
mass (r = –0.26; p < 0.05). 
There was no correlation between plasma vaspin levels 
and serum glucose and insulin concentrations as well as 
HOMA-IR values in both all study groups and both PCOS 
and Non-PCOS groups analyzed separately. 
Multivariable regression analyses 
Multivariable, stepwise backward regression analyses 
revealed that waist circumference but no other anthropo-
metric parameters, as well as HOMA-IR values, explained 
18.0% of plasma vaspin levels variability. 
DISCUSSION
The results presented in this study demonstrate lower 
vaspin levels in PCOS women in corresponding, accord-
ing to nutritional status, Non-PCOS subgroups. In addition, 
vaspin levels were affected by measures of nutritional sta-
tus, but only in Non-PCOS subgroup. They were inversely 
proportional to body mass, and lower in normal weight 
than obese Non-PCOS. 
It should be noted, that it is the first study that showed 
lower vaspin levels in PCOS women independently from 
nutritional status. In four published studies higher vaspin 
levels in PCOS women were described [14–17] and in two 
there were no differences between PCOS and Non-PCOS 
subjects [18, 19]. In addition, we found striking differences 
in vaspin levels in previously published studies. Only in one 
study performed in 12 subjects the median of vaspin levels 
was similar to obtained in our study [14]. While in Turkish 
subjects mean vaspin levels were more than two times 
higher in PCOS group and in the control group almost five 
times lower than in our study [15]. Similar, differences were 
observed in Greek cohorts [16]. 
Contrary, to previously published studies [17] in multi-
ple regression analysis we observed an inverse association 
between vaspin levels and waist circumference in PCOS 
subjects. In addition, contradictory to the other studies, we 
did not observe an association between vaspin levels and 
BMI values [8, 17]. These differences are difficult to explain. 
On the one hand, it may be a result of small study group 
sizes [14, 15], the differences in nutritional status between 
study and control groups (mean BMI 5 kg/m2 lower in control 
group) [16, 17] and race. On the other hand, it may be the 
result of different ELISA kits used to vaspin levels measure-
ments, produced by different manufacturers. The lack of 
studies comparing specificity of kits produced for vaspin 
levels assessment should be raised. 
Furthermore, we did not observe the association be-
tween serum glucose and insulin concentrations as well as 
HOMA-IR values and circulating vaspin levels. It is opposite 
to some published studies that show that HOMA-IR values 
were proportional to vaspin levels in PCOS women [17–19] 
but in accordance with the results of other studies [15, 17]. 
The association between insulin resistance or glucose me-
tabolism and circulating vaspin levels is not clear. It should be 
noted that only Youn et al. [8] shown an association between 
HOMA-IR and vaspin levels in group with normal glucose tol-
erance. In addition, Tan et al. [14] found that vaspin synthesis 
is stimulated by glucose in omental adipocytes. Moreover, 
vaspin mRNA expression but not its circulating levels were 
proportional to insulin resistance. Therefore, we hypoth-
esized that increased vaspin levels may be a compensatory 
mechanism in the development of the early stage of insulin 
resistance, that run out over time. This hypothesis is par-
tially supported by the observed lower vaspin levels in PCOS 
subjects and its higher levels in obese than normal-weight 
Non-PCOS women. However, further studies with follow-up 
are necessary to confirm our hypothesis. 
The main limitations of the study are the small sizes of 
study subgroups and the lack of the assessment of the body 
fat visceral and subcutaneous using DEXA or CT scanner. Addi-
tionally, only selected adipokine vaspin was analyzed thus the 
assessment of the association between hormonal disturbances 
of adipose tissue and it’s inflammation was not possible. 
CONCLUSIONS
PCOS occurrence is associated with decreased vaspin 
levels in young women. The influence of nutritional status 
on vaspin level observed in Non-PCOS is abolished in PCOS 
women, possibly by the coexisting insulin resistance. 
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